Monte Competitors

Stocks . USA . 
Stock . Monte Rosa Therapeutics
GLUE Stock  USD 6.27  0.06  0.97%   
Monte Rosa Therapeutics competes with Nkarta, Lyell Immunopharma, Generation Bio, Sana Biotechnology, and Design Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Monte Rosa competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Monte Rosa to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Monte Rosa Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Monte Rosa competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Monte Rosa's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.986.3110.64
Details
Intrinsic
Valuation
LowRealHigh
4.158.4812.81
Details

Monte Rosa Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Monte Rosa and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Monte and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Monte Rosa Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
IKNA
+ 0.89
GBIO
IKNA
+ 0.84
HOWL
HOWL
+ 0.79
GBIO
STOK
+ 0.73
HOWL
STOK
+ 0.69
GBIO
DSGN
+ 0.68
GBIO
  
High negative correlations   
DSGN
- 0.67
SANA
LYEL
- 0.46
NKTX
STOK
- 0.43
LYEL
STTK
- 0.42
GBIO
HOWL
- 0.39
SANA
STTK
- 0.35
NKTX

Risk-Adjusted Indicators

There is a big difference between Monte Stock performing well and Monte Rosa Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Monte Rosa's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NKTX  3.26 (0.49) 0.00 (0.70) 0.00 
 0.00 
 7.33 
(7.26)
 20.74 
LYEL  3.55  0.02  0.00 (0.10) 0.00 
 0.00 
 6.56 
(7.69)
 17.43 
GBIO  3.71 (1.20) 0.00 (0.95) 0.00 
 0.00 
 6.74 
(7.89)
 22.69 
SANA  7.80  1.80  0.31 (1.96) 5.49 
(11.18)
 10.15 
(10.07)
 176.41 
DSGN  4.20 (0.25) 0.00 (0.45) 0.00 
 0.00 
 8.72 
(9.07)
 24.91 
HOWL  2.86 (0.32) 0.00 (0.35) 0.00 
 0.00 
 6.08 
(7.10)
 23.66 
IKNA  2.05 (0.23) 0.00 (0.67) 0.00 
 0.00 
 4.65 
(3.73)
 16.13 
STOK  3.50 (0.32) 0.00 (0.32) 0.00 
 0.00 
 7.03 
(9.08)
 20.29 
FHTX  3.73 (0.03) 0.00 (0.12) 0.00 
 0.00 
 9.05 
(7.58)
 26.22 
STTK  5.45  0.49  0.07  0.63  6.71 
(6.72)
 11.21 
(7.58)
 50.15 
All Fundamental Data

Monte Rosa Competitive Analysis

The better you understand Monte Rosa competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Monte Rosa's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Monte Rosa's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GLUE NKTX LYEL GBIO SANA DSGN HOWL IKNA STOK FHTX
 0.97 
 6.27 
Monte
 3.49 
 1.66 
Nkarta
 3.28 
 0.59 
Lyell
 5.88 
 0.48 
Generation
 10.15 
 2.93 
Sana
 0.21 
 4.71 
Design
 0.83 
 1.20 
Werewolf
 1.47 
 1.34 
Ikena
 6.04 
 8.60 
Stoke
 1.12 
 4.43 
Foghorn
Market Volatility
(90 Days Market Risk)
Slightly risky
Relatively risky
Abnormally volatile
Very risky
Extremely Dangerous
Relatively risky
Unstable
Very risky
Somewhat reliable
Moderately volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
About Average
Very High
Very High
Very High
High
Average
Very High
Above Average
About Average
Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Cautious Hold
Hold
Cautious Hold
Strong Sell
Current Ratio
20.11
31.66
13.26
17.93
5.09
48.96
5.08
6.98
10.46
6.84
Net Asset
303.75 M
378.88 M
490.86 M
374.76 M
565.3 M
252.09 M
126.93 M
141.51 M
228.34 M
283.98 M
EBITDA
(137.09 M)
(120.48 M)
(3.31 M)
(133.3 M)
(252.39 M)
(62.38 M)
(64.05 M)
(58.97 M)
(112.3 M)
(97.17 M)
Operating Margin
-2.88
N/A
N/A
-2.21
N/A
N/A
-39.04
-97.55
-6.13
-8.41
Current Valuation
183.03 M
(80.46 M)
(132.56 M)
(56.79 M)
489.86 M
24.78 M
(19.67 M)
(51.23 M)
192.66 M
42.53 M
Price To Book
1.86
0.28
0.47
0.33
2.03
1.11
0.74
0.52
1.85
10.71
Retained Earnings
(365.89 M)
(435.43 M)
(1.35 B)
(571.38 M)
(1.34 B)
(227.21 M)
(414.59 M)
(331.62 M)
(401.85 M)
(558.18 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.5
0.9
-0.42
2.73
1.64
1.78
0.38
0.5
0.99
3.13
Number Of Employees
133
159
14
174
328
54
46
14
110
112
Shares Outstanding
61.44 M
70.57 M
295.23 M
66.79 M
223.27 M
56.76 M
44.83 M
48.26 M
52.97 M
55.61 M
Cash Flow From Operations
(43.8 M)
(86.16 M)
(162.39 M)
(52.74 M)
(253.58 M)
(43.1 M)
(56.19 M)
(46 M)
(81.07 M)
(100.41 M)
Total Debt
46.04 M
88.34 M
50.99 M
97.89 M
104.1 M
1.53 M
10.99 M
7.52 M
2.06 M
37.13 M
Return On Equity
-0.61
-0.3
-0.66
-0.86
-0.93
-0.19
-0.76
-0.37
-0.52
-4.7
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.28
-0.17
-0.22
-0.19
-0.31
-0.14
-0.3
-0.22
-0.28
-0.22
Number Of Shares Shorted
8.03 M
9.62 M
9.65 M
2.5 M
44.33 M
3.14 M
1.87 M
154.14 K
10.09 M
965.32 K
Book Value Per Share
3.35
6.11
1.3
1.57
1.31
4.27
1.64
2.78
4.38
-0.82
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
303.75 M
378.88 M
490.86 M
374.76 M
565.3 M
252.09 M
126.93 M
141.51 M
228.34 M
283.98 M
Debt To Equity
0.16
0.17
0.077
0.27
0.18
0.011
0.12
0.036
0.026
2.19
Short Ratio
17.6
11.27
6.22
5.94
14.01
23.66
7.11
0.93
13.49
6.16
Target Price
16.38
14.5
0.8
7.0
9.8
7.33
10.67
3.0
23.88
11.5
Shares Owned By Institutions
99.3
99.99
65.94
81.8
94.44
59.33
63.32
87.76
95.4
72.6
Market Capitalization
381.52 M
117.14 M
179 M
34.2 M
592.78 M
267.92 M
54.24 M
65.63 M
429.56 M
249.14 M
Price To Earning
1.91
N/A
3.66
N/A
N/A
N/A
0.84
3.89
N/A
N/A
Price To Earnings To Growth
N/A
N/A
0.68
N/A
N/A
N/A
-0.06
N/A
0.27
N/A
Price To Sales
25.48
1000000.0
2934.38
1.84
N/A
22642.01
28.78
99.59
25.66
11.02
Net Income
(135.35 M)
(117.5 M)
(342.99 M)
(126.61 M)
(283.25 M)
(49.59 M)
(70.52 M)
(49.23 M)
(104.7 M)
(86.62 M)
Earnings Per Share
-1.78
-1.83
-1.31
-2.19
-1.4
-0.88
-1.63
-1.02
-2.08
-1.58
Shares Owned By Insiders
0.7
5.26
13.7
14.4
8.65
36.35
6.08
4.54
4.6
18.97
Revenue
N/A
N/A
61 K
5.9 M
N/A
N/A
1.89 M
N/A
8.78 M
22.6 M
Working Capital
189.62 M
229.74 M
325.81 M
232.7 M
149.03 M
239.58 M
97.89 M
116.39 M
184.52 M
182.61 M
Cash And Equivalents
294.14 M
412.95 M
655.56 M
301.17 M
484.8 M
359.38 M
145.71 M
192.81 M
275.63 M
373.5 M
Cash Per Share
6.32
8.49
2.64
5.07
2.57
6.45
4.93
5.32
6.99
8.94
Gross Profit
16.78 M
(36.22 M)
61 K
(41.44 M)
N/A
(44.35 M)
(51.2 M)
(39.91 M)
16.74 M
(71.93 M)
Day Typical Price
6.27
1.69
0.6
0.49
2.83
4.79
1.21
1.35
8.5
4.52
Accumulation Distribution
0.0467
0.0571
0.0484
0.0769
0.11
0.0505
0.056
0.0362
0.0619
0.0719
Market Facilitation Index
0.3
0.1
0.03
0.04
0.32
0.25
0.07
0.05
0.54
0.34
Daily Balance Of Power
0.2
(0.60)
(0.67)
(0.75)
0.8438
(0.04)
(0.14)
(0.40)
0.9074
(0.15)
Period Momentum Indicator
0.06
(0.06)
(0.02)
(0.03)
0.27
(0.01)
(0.01)
(0.02)
0.49
(0.05)
Rate Of Daily Change
1.01
0.97
0.97
0.94
1.1
1.0
0.99
0.99
1.06
0.99
Day Median Price
6.27
1.7
0.61
0.5
2.78
4.83
1.21
1.36
8.45
4.56
Price Action Indicator
0.03
(0.07)
(0.03)
(0.04)
0.29
(0.12)
(0.02)
(0.03)
0.39
(0.16)
Coefficient Of Variation
(1,761)
(760.99)
(3,826)
(352.69)
1124.27
(1,817)
(894.26)
(1,020)
(1,016)
(2,090)
Mean Deviation
3.34
3.26
3.55
3.71
7.8
4.2
2.86
2.05
3.5
3.73
Jensen Alpha
(0.14)
(0.49)
0.0164
(1.20)
1.8
(0.25)
(0.32)
(0.23)
(0.32)
(0.03)
Total Risk Alpha
0.2862
(0.04)
0.4277
(0.76)
4.61
0.3953
0.0449
0.0645
0.1181
0.3788
Sortino Ratio
N/A
N/A
N/A
N/A
0.3071
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
43.23
N/A
N/A
N/A
N/A
N/A
Standard Deviation
4.33
4.37
4.42
4.75
21.59
5.77
4.09
2.74
4.78
5.02
Kurtosis
0.237
2.06
(0.61)
0.0217
50.63
1.2
2.34
1.29
1.02
1.29
Potential Upside
6.5
7.33
6.56
6.74
10.15
8.72
6.08
4.65
7.03
9.05
Treynor Ratio
(0.24)
(0.70)
(0.1)
(0.95)
(1.96)
(0.45)
(0.35)
(0.67)
(0.32)
(0.12)
Maximum Drawdown
19.92
20.74
17.43
22.69
176.41
24.91
23.66
16.13
20.29
26.22
Variance
18.71
19.06
19.51
22.6
466.17
33.33
16.76
7.5
22.89
25.23
Market Risk Adjusted Performance
(0.23)
(0.69)
(0.09)
(0.94)
(1.95)
(0.44)
(0.34)
(0.66)
(0.31)
(0.11)
Risk Adjusted Performance
(0.04)
(0.11)
(0.01)
(0.24)
0.087
(0.04)
(0.09)
(0.08)
(0.08)
(0.03)
Skewness
0.2302
0.9844
(0.03)
0.304
6.81
0.352
0.6796
0.3201
(0.51)
0.5512
Semi Deviation
N/A
N/A
N/A
N/A
5.49
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.03)
(0.11)
(0)
(0.26)
0.0935
(0.04)
(0.09)
(0.06)
(0.08)
(0.03)
Value At Risk
(7.40)
(7.26)
(7.69)
(7.89)
(10.07)
(9.07)
(7.10)
(3.73)
(9.08)
(7.58)
Expected Short fall
N/A
N/A
N/A
N/A
(11.18)
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
6.58
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
30.12
N/A
N/A
N/A
N/A
N/A

Monte Rosa Competition Performance Charts

Five steps to successful analysis of Monte Rosa Competition

Monte Rosa's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Monte Rosa Therapeutics in relation to its competition. Monte Rosa's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Monte Rosa in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Monte Rosa's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Monte Rosa Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Monte Rosa position

In addition to having Monte Rosa in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Wireless Thematic Idea Now

Wireless
Wireless Theme
Companies providing wireless technology and communication services. The Wireless theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
How To Invest In Monte
Details
Is Monte Stock a good investment?
Details
What is Monte Rosa's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Monte Rosa Correlation with its peers.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY